ClinVar Miner

Submissions for variant NM_000138.5(FBN1):c.7726C>T (p.Arg2576Cys)

dbSNP: rs147195031
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen FBN1 Variant Curation Expert Panel, ClinGen RCV000029780 SCV005387628 pathogenic Marfan syndrome 2024-08-22 reviewed by expert panel curation The NM_00138 c.7726C>T is a missense variant in FBN1 predicted to cause a substitution of an arginine by cysteine at amino acid 2576 (p.Arg2576Cys) within a calcium binding EGF-like domain of the protein (PM1). This variant was found in a proband with aortic aneurysm and dissection and ectopia lentis, which is a highly specific phenotype for Marfan syndrome (MFS) (Internal lab data; PP4). This variant has been reported nine times in ClinVar: five times as pathogenic, three times as likely pathogenic, and once as uncertain significance (Variation ID: 36118). This variant has also been identified in at least 9 individuals with clinical diagnosis of MFS as well as in individuals with clinical features of MFS (PMID 24161884, 31830381, 33711475, 23278365, 33824467, 37042257, internal lab data; PS4). In three individuals with MFS, this variant was reported to be de novo, without confirmation of parental relationships (internal lab data, Prevention Genetics ClinVar, PM6). In at least 5 families with MFS, the variant was found to segregate with MFS and/or clinical features of MFS in several affected relatives (Internal lab data, Laboratory Corporation of America ClinVar, PP1_Strong). This variant is present in in 1/250782 (0.0004%) of alleles tested in gnomAD but did not pass the quality control criteria in the exome subset (PM2_Sup; https://gnomad.broadinstitute.org/ v2.1.1). Computational prediction tools and conservation analysis are inconclusive with regards to a possible impact on this variant’s protein function and structure (REVEL: 0.686). The constraint z-score for missense variants affecting FBN1 is 5.06 (PP2). In summary, this variant meets criteria to be classified as pathogenic for Marfan syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen FBN1 VCEP: PS4, PP1_Strong, PM1, PM6, PM2_Sup, PP2, PP4
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003492302 SCV000052434 pathogenic Marfan Syndrome/Loeys-Dietz Syndrome/Familial Thoracic Aortic Aneurysms and Dissections 2023-12-05 criteria provided, single submitter clinical testing Variant summary: FBN1 c.7726C>T (p.Arg2576Cys) results in a non-conservative amino acid change, introducing a novel cysteine in the EGF-like domain (IPR000742), which is functionally important to form disulfide bonds in FBN1. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.4e-06 in 1461742 control chromosomes (gnomAD). This variant was found to co-segregate with Marfan Syndrome in 3 patients in our internal testing family with detailed clinical information. Additionally, c.7726C>T has been reported in the literature in at least three individuals affected with Marfan Syndrome who met Ghent criteria (e.g. Aalberts_2014, Xu_2020, Mariucci_2021), one suspected MFS patient who didn't meet Ghent criteria (Baudhuin_2015), and in at least one individual with sporadic thoracic aortic aneurysm and dissections (e.g. Guo_2015). These data indicate that the variant is very likely to be associated with disease. The variant has also been reported in the homozygous state in a patient who had clinical features that were not considered typical for Marfan Syndrome and a lack of MFS symptoms in her parents (mother confirmed to carry this variant in heterozygous state; Hogue_2012) which suggests the pathogenicity of this variant in dominant form may be modified in certain conditions. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 24161884, 25652356, 26787436, 26272055, 23278365, 33824467, 33711475, 31830381). Eight submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Six submitters classified the variant as pathogenic/likely pathogenic and two classified it as uncertain significance. Based on the evidence outlined above, the variant was classified as pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV000539171 SCV000627996 pathogenic Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection 2023-07-22 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function. ClinVar contains an entry for this variant (Variation ID: 36118). This missense change has been observed in individuals with Marfan syndrome (PMID: 23278365, 24161884, 26272055, 26787436; Invitae). This variant is present in population databases (rs147195031, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 2576 of the FBN1 protein (p.Arg2576Cys).
Blueprint Genetics RCV000788741 SCV000927966 pathogenic not provided 2018-09-28 criteria provided, single submitter clinical testing
Department of Vascular Biology, Beijing Anzhen Hospital RCV001374808 SCV001439509 likely pathogenic Isolated thoracic aortic aneurysm 2018-09-01 criteria provided, single submitter research
GeneDx RCV000788741 SCV001805784 likely pathogenic not provided 2024-05-14 criteria provided, single submitter clinical testing Introduces a new cysteine residue within a calcium-binding EGF-like domain of the FBN1 gene, which may affect disulfide bonding and is predicted to alter the structure and function of the protein; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (PMID: 12938084); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 16571647, 17701892, 12938084, 24698609, 26787436, 16677079, 15161917, 4750422, 26272055, 33824467, 23278365, 24161884)
Ambry Genetics RCV002399340 SCV002670581 pathogenic Familial thoracic aortic aneurysm and aortic dissection 2022-04-28 criteria provided, single submitter clinical testing The p.R2576C pathogenic mutation (also known as c.7726C>T), located in coding exon 62 of the FBN1 gene, results from a C to T substitution at nucleotide position 7726. The arginine at codon 2576 is replaced by cysteine, an amino acid with highly dissimilar properties, and is located in the cb EGF-like #41 domain. The majority of FBN1 mutations identified to date have involved the substitution or generation of cysteine residues within cbEGF domains (Vollbrandt T et al. J Biol Chem. 2004;279(31):32924-32931). This variant has been detected in several individuals with Marfan syndrome (MFS), in MFS cohorts, and in individuals with aortic aneurysm/dissection or other features of MFS (Aalberts JJ et al. Gene. 2014;534(1):40-3; Baudhuin LM et al. J Hum Genet. 2015 May;60(5):241-52; Guo J. Sci Rep. 2015 Aug;5:13115; Franken R et al. Eur Heart J. 2016 Nov;37(43):3285-3290; Li Y et al. Eur J Hum Genet. 2021 07;29(7):1129-1138; Ambry internal data). This variant was observed in a homozygous patient with severe features of MFS and other clinical findings; however, the patient's heterozygous mother reportedly did not have MFS phenotype (Hogue J et al. Clin Genet. 2013;84(4):392-3). Based on internal structural analysis, this variant may interfere with disulfide formation by forming alternative disulfide bonds, thereby perturbing the structure of a flexible loop; however, the role of this loop and its structure on the function of FBN1 is unclear (Bersch B et al. Biochemistry, 1998 Feb;37:1204-14). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Revvity Omics, Revvity RCV000788741 SCV003832856 likely pathogenic not provided 2022-04-25 criteria provided, single submitter clinical testing
OMIM RCV000083258 SCV000115337 pathogenic Marfan syndrome, autosomal recessive 2013-10-01 no assertion criteria provided literature only
Center for Medical Genetics Ghent, University of Ghent RCV000029780 SCV000787353 uncertain significance Marfan syndrome 2017-11-07 flagged submission clinical testing
PreventionGenetics, part of Exact Sciences RCV004532416 SCV004730048 pathogenic FBN1-related disorder 2024-01-20 no assertion criteria provided clinical testing The FBN1 c.7726C>T variant is predicted to result in the amino acid substitution p.Arg2576Cys. This variant was reported in multiple individuals with Marfan syndrome and/or related aortopathies (Table S1, Aalberts et al. 2014. PubMed ID: 24161884; Guo et al. 2015. PubMed ID: 26272055; Table S2, Franken et al. 2016. PubMed ID: 26787436; Table S3, Li. 2021 et al. PubMed ID: 33824467). This variant was also documented in the apparently homozygous state in an individual with severe Marfan syndrome. The mother was reported to be a heterozygous carrier without clinical features of Marfan syndrome and the father was not available for examination (Hogue et al. 2013. PubMed ID: 23278365). At PreventionGenetics, this variant was identified to have occurred de novo in an individual with Marfan syndrome (internal data). This variant creates a cysteine residue that is located within the epidermal growth factor-like domain of the FBN1 protein and missense variants in FBN1 that substitute or create a cysteine residue are well-documented to cause Marfan syndrome (Dietz and Dietz. 1993. PubMed ID: 20301510; Comeglio et al. 2007. PubMed ID: 17657824; Stheneur et al. 2009. PubMed ID: 19293843). This variant is reported in 0.010% of alleles in individuals of Ashkenazi Jewish descent in gnomAD. This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.